cerkalo
» » Obesity and Metabolic Disorders (Solvay Pharmaceuticals Conferences) (Solvay Pharmaceutical Conferences)

Obesity and Metabolic Disorders (Solvay Pharmaceuticals Conferences) (Solvay Pharmaceutical Conferences) download ebook

by J. Antel,N. Finer

Obesity and Metabolic Disorders (Solvay Pharmaceuticals Conferences) (Solvay Pharmaceutical Conferences) download ebook
ISBN:
1586035355
ISBN13:
978-1586035358
Author:
J. Antel,N. Finer
Publisher:
IOS Press (September 1, 2005)
Language:
Pages:
228 pages
ePUB:
1798 kb
Fb2:
1229 kb
Other formats:
lrf azw mobi lit
Category:
Medicine
Subcategory:
Rating:
4.3

Solvay Pharmaceuticals Conferences. This series is published in cooperation with Solvay Pharmaceuticals Conferences and covers topics in the field of Biochemistry and Medicine.

Solvay Pharmaceuticals Conferences. Recommend this title to your librarian.

Overweight and obesity in humans emerge as contemporary risks for diabetes type-2, cardiovascular disease and cancer. There seems to be consensus that on the background of modern life styles, genes that have been selected over the millions of years of human evolution render humans prone to obesity. These same genes which support higher accumulation of energy conferred substantial benefits to our ancestors at times of famine.

Obesity has reached pandemic proportions. Changes in lifestyles and changes in dietary habits, as well as unification of diets contribute to the rising prevalence of obesity and the associated metabolic syndrome. Overweight and obesity in humans emerge as contemporary risks for diabetes type-2, cardiovascular disease and cancer. The reasons for obesity are not well understood.

From active ingredients to packaging, we offer the pharmaceutical industry a broad range of solutions. Solvay's pharmaceutical segment covers many different applications and functionalities to better serve this industry.

The reframing of obesity as an inflammatory condition has had a wide impact on our conceptualization of obesity-associated diseases.

Solvay Pharmaceuticals . The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic. Solvay Pharmaceuticals. a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics .

See a Problem? We’d love your help.

Resource information. Title proper: Solvay pharmaceuticals conferences. Country: Netherlands. Last modification date: 06/11/2010. Type of record: Confirmed. ISSN Center responsible of the record: ISSN Centrum Nederland.

The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic enzymes. We aim for marketing excellence in gastroenterology and men’s and women’s health. Its 2006 sales were EUR . billion and it employs approximately 10,000 people worldwide.

Obesity has reached pandemic proportions. Changes in lifestyles and changes in dietary habits, as well as unification of diets contribute to the rising prevalence of obesity and the associated metabolic syndrome. Overweight and obesity in humans emerge as contemporary risks for diabetes type-2, cardiovascular disease and cancer. There seems to be consensus that on the background of modern life styles, genes that have been selected over the millions of years of human evolution render humans prone to obesity. These same genes which support higher accumulation of energy conferred substantial benefits to our ancestors at times of famine. By harnessing the knowledge on glucose metabolism we recognized that regulation of energy storage is a key process. We believe that the brain is critically involved in the regulation of energy metabolism. Progress in knowledge on energy metabolism has contributed to the invention of pharmacological measures aiming to help humans suppress food intake and control body weight. Most of these measures have been recalled due to several side effects, such as; increased hart rates an blood pressure, withdrawal symptoms, hypertension and kidney stones. Current understanding of the mechanism of action of cannabinoid CB1 antagonists is pointing towards the brain. It is postulated that hypothalamic CB1 receptors are responsible for pharmacological effects of CB1 antagonists on fat tissue. It is our hope that, in the near future, novel drugs will demonstrate adequate efficacy in aiding and maintaining weight loss, enable a truly effective and safe long-term therapy without serious side effects.

IOS Press is an international science, technical and medical publisher of high-quality books for academics, scientists, and professionals in all fields.

Some of the areas we publish in:

-Biomedicine -Oncology -Artificial intelligence -Databases and information systems -Maritime engineering -Nanotechnology -Geoengineering -All aspects of physics -E-governance -E-commerce -The knowledge economy -Urban studies -Arms control -Understanding and responding to terrorism -Medical informatics -Computer Sciences